Updated 08:05 GMT, 20 Nov 2026 SPX 7,175.83 -2.02% NDX 26,517.05 -2.21% VIX 28.44 +15.80% GOLD 3,574.90 -3.00% CL 82.63 -0.70% BTC 61,735.58 -0.27%
NAS100 26,517 −2.21% S&P 7,176 −2.02% GOLD $3,575 −3.00% BTC $61,736 −0.27% VIX 28.44 +15.80% latest tape · as of 08:05 UTC
The Screen · Consumer Cyclical · Specialty Retail

Bath & Body Works, Inc. logoBath & Body Works, Inc.

BBWI · the NYSE · USD · Market cap $4.3B · 9,071 employees

Bath & Body Works, Inc.

FAIL · Does not pass the screen
18.91 USD

Price as of 19 Nov 2026Daily close, not a live quote

Screened 2026-11-19 · the tape above runs as of 08:05 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price18.91 USD at the 19 Nov 2026 close
  • Our value readUndervalued vs our fair value, as of 19 Nov 2026
  • Our regime readAccumulation, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans heavily to calls (put/call 0.43)
  • Last reviewed19 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $22.26 to $36.17, base estimate $23.52 (screen dated 2026-11-19).

Current read
Accumulation ?
Undervalued · screened 2026-11-19
  • Trend Accumulation
  • Insiders insiders sold, $14, latest filing 2026-10-16
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 0.43, read 2026-11-18
  • Ethical does not pass the values gate
Price18.91 USD
Fair value23.52
Ethical score10.0/100
Value readUndervaluedas of 19 Nov 2026
Our investment reviews on this name
2026-11-15Read Accumulation21.39-11.6% to today Markup gives way to Accumulation first Accumulation read since October
2026-10-25Read Markup20.44-7.5% to today Accumulation gives way to Markup first Markup read since October
2026-10-18Read Accumulation20.44-7.5% to today Markup gives way to Accumulation after a 20% rise in 7 days
2026-10-11Read Markup17.02+11.1% to today ✓Markdown gives way to Markup first Markup read since August

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its accumulation label.

Bath & Body Works, Inc. holds its Accumulation at $18.91. The statistical read favours the sellers, held for 193 days.

As held on the ledger · 2026-11-19
PhaseAccumulation
Quantitative stateThe statistical read favours the sellers, held for 193 days
Price at the screen$18.91
Valuation5.62 trailing · 7.68 forward price to earnings
Values screenFAIL · score 10.0
Beta1.33
The Workings

Five Screens: BBWI's Results

FAIL. Debt ratio

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 135.05% Below 33% Fail
Interest-bearing cash 25.98% Below 33% Pass
Receivables 0.00% Below 49% Pass

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Falls Short, in Plain English

Bath & Body Works,'s business is in a permissible area, but its interest-bearing debt is about 135% of the company, well over the ~33% line, so it does not pass on the financial screens.

Read as at 2026-11-19. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when BBWI's ethical verdict changes

Today BBWI does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Undervalued vs our fair value, as of 19 Nov 2026: it trades at roughly a 20% discount to our $23.52 fair value, weak competitive moat.

Model construction and limits: fair-value methodology.

22.26Conservative23.52Base case36.17Growth case 18.91Price

Fair value range in USD, drawn from the 2026-11-19 screen. The gold marker is the market price at the same screen. A 19.6% discount to the base estimate.

The Street's Range
17.00Street low 22.00Street average 54.00Street high 18.91Price

Third-party analyst targets: 15 covering, consensus Hold. The average target sits +16% from the screen price.

Reading the gap · Both our model and the analysts see meaningful upside from here.

Price History & Projections

Where our models see it going: fair-value estimate $23.52, with a range of $22.26 to $36.17, dated to the 2026-11-19 screen.

How our estimate and third-party targets differ.

The Business, in Plain Words

Debt burden outweighs any bargain in bath products

Every time someone reaches for a three wick candle or a bottle of lotion the retailer behind it is already carrying more debt than its balance sheet can comfortably support. We pass because the company fails the ethical screen on that leverage, leaving no margin for the kind of shocks that hit specialty retail hard.

Revenue is shrinking three percent while the forward multiple sits at seven times earnings. That looks cheap until you remember this is a cyclical business with a weak moat and margins that can compress quickly when spending slows. The fifteen analysts see it as a hold with targets barely above the current price, which tells you the market is not pricing in much recovery.

High debt plus negative growth creates exactly the sort of value trap that appears attractive on paper but rarely rewards patience. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E7.7xvery cheap relative to earnings
Trailing P/E5.6xvery cheap relative to earnings
EPS, trailing3.80
EPS, forward2.78
Revenue growth-2.3%revenue is shrinking
Profit margin10.8%thin but positive margins
FCF yield17.75%
Dividend yield4.35%
Current ratio1.20adequate liquidity, worth monitoring
Beta1.33moves a little more than the market
Short interest, float0.09%
52-week range14.28 - 24.94
MoatWEAK
Market cap$4.3B
Employees9,071

BBWI-specific watchpoints · The things to watch: it already moves more than the market on an average day.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-19 Accumulation $18.66 +1.4% Entry 23

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (15 analysts) rates it hold, with a mean price target of $25. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-18 Accumulation $18.40 -14.0% Entry 22

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 14.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (14 analysts) rates it hold, with a mean price target of $26. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-17 Accumulation $21.39 +0.0% Entry 21

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (14 analysts) rates it hold, with a mean price target of $26. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-16 Accumulation $21.39 +0.0% Entry 20

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (14 analysts) rates it hold, with a mean price target of $26. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-15 Accumulation · changed $21.39 +0.0% Entry 19

The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (14 analysts) rates it hold, with a mean price target of $26. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-14 Markup $21.39 +1.5% Entry 18

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (14 analysts) rates it hold, with a mean price target of $26. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-13 Markup $21.08 -2.9% Entry 17

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 2.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (14 analysts) rates it hold, with a mean price target of $26. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-12 Markup $21.72 +1.7% Entry 16

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (14 analysts) rates it hold, with a mean price target of $26. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-08 Markup $21.36 -6.2% Entry 15

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 6.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (14 analysts) rates it hold, with a mean price target of $26.

2026-11-01 Markup $22.77 +11.4% Entry 14

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 11.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 29%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (14 analysts) rates it hold, with a mean price target of $26.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Latest News · What the Market Is Reading on BBWI

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in BBWI's Space

Screened names in the same industry · explore each on its own page.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · BBWI
DateInsiderTitleTypeSharesValue
2026-10-16 Nash Sarah E Dir S - Sale 1 $14
2026-05-19 MAZUREK THOMAS E Officer 6,616 ·
2026-03-12 MAZUREK THOMAS E Officer 40,921 ·
2026-03-12 HEAF DANIEL Chief Executive Officer 212,993 ·
2026-03-12 BORATTO EVA C Chief Financial Officer 115,815 ·
2025-11-24 NASH SARAH E Director 10,000 $155,800
2025-11-24 SYMANCYK JAMES KEVIN Director 22,500 $350,550
2025-11-21 VOSKUIL STEVEN E Director 20,000 $300,700
2025-11-21 STEINOUR STEPHEN D Director 6,700 $99,528
2025-11-21 HONDAL FRANCIS A Director 3,343 $50,128

Public filings, recorded as found. The full tape lives at Insider Intelligence.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $19.84 -6.0% · $941 -6.0%
2 months $17.40 +7.2% · $1,072 +7.2%
3 months $19.44 -4.0% $0.20 $970 -3.0%
6 months $17.38 +7.4% $0.40 $1,097 +9.7%
1 year $20.22 -7.7% $0.80 $962 -3.8%
2 years $29.37 -36.5% $1.60 $690 -31.0%
3 years $27.02 -31.0% $2.20 $772 -22.8%
5 years $67.45 -72.3% $3.80 $333 -66.7%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever BBWI does next, these words stay.

Bath & Body Works, Inc. · BBWI · Accumulation · $18.91
Recorded 2026-11-19 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.